uniQure N.V.QURE stock score: 45/100

$20.23 · -0.34% · Scored Nov 19, 2026

Technical
29
Fundamental
49
News
54

The reading

uniQure (QURE) scores 45 out of 100, which reads weak, higher than 34% of Healthcare stocks and 32% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 49, technicals 29.

Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.

On the daily chart, trend-following indicators average 15 and contrarian oscillators 67 — a split worth reading before trusting the technical total.

News sentiment is neutral at 54; it is shown, not counted in the composite.

Since Aug 22, 2026 the composite has ranged from 35 to 55, and it is down 9 points over the period.

About uniQure

uniQure (QURE) is a Netherlands-based gene therapy company that develops one-time treatments delivered with adeno-associated virus vectors. Its main program is AMT-130, an investigational therapy for Huntington’s disease that is infused directly into the brain and is designed to reduce production of the harmful huntingtin protein. Its clinical results have been measured against an external control group of untreated patients rather than a placebo arm, and whether regulators accept that comparison is central to its path to approval. The company developed Hemgenix, a gene therapy for hemophilia B that CSL Behring sells under license, and it has sold part of its royalty interest in that product to a royalty investor. It earns limited revenue today, mainly from royalties and collaboration income, and funds research largely through stock offerings and its cash reserves.

uniQure competes with Roche, Novartis, Wave Life Sciences and other companies developing drugs that lower huntingtin levels, as well as with gene therapy developers in its other disease areas. Its edge rests on years of patient follow-up with AMT-130, experience manufacturing viral vectors and expertise in delivering gene therapy to the brain. Investors who follow QURE stock tend to watch the regulatory path for AMT-130 in the United States and Europe. Updated trial data and the reliability of the external comparison are closely followed. Cash runway and launch preparations are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward QURE’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

49

Pulling it up

  • Quick ratio measures a company's ability to meet short-term obligations with liquid assets.

  • Price target score compares the current stock price to analyst consensus targets.

  • Current assets divided by current liabilities: the ability to pay short-term bills.

Holding it back

  • Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.

  • Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.

  • EV/Revenue compares the whole company's value, debt included, with its sales.

37 weighted scorers; 2 had no data today and are left out rather than counted as zero.

Technical · daily

22

Pulling it up

  • Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.

  • Bollinger Bands (20-period) plot standard deviations above and below a moving average.

  • Money Flow Index (14-period) is a volume-weighted RSI that identifies overbought and oversold conditions.

Holding it back

  • SMA 50 Trend evaluates the slope of the 50-period moving average.

  • Simple Moving Average (200-period) is the most widely followed long-term trend indicator.

  • Simple Moving Average (100-period) provides a longer-term perspective on price trends.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

News · shown, not counted

Global News
54

Technical score by timeframe

ChartScoreWeight
Hourly321
Daily223
Weekly272
Monthly422

Composite score, last 90 days

05010045Aug 22, 2026Nov 19, 2026Aug 22, 2026: 54Aug 23, 2026: 54Aug 24, 2026: 53Aug 25, 2026: 55Aug 26, 2026: 54Aug 27, 2026: 54Aug 28, 2026: 53Aug 29, 2026: 54Aug 30, 2026: 54Aug 31, 2026: 52Sep 1, 2026: 53Sep 2, 2026: 52Sep 3, 2026: 52Sep 4, 2026: 51Sep 5, 2026: 51Sep 6, 2026: 51Sep 7, 2026: 51Sep 8, 2026: 53Sep 9, 2026: 52Sep 10, 2026: 50Sep 11, 2026: 51Sep 12, 2026: 51Sep 13, 2026: 51Sep 14, 2026: 51Sep 15, 2026: 49Sep 16, 2026: 48Sep 17, 2026: 51Sep 18, 2026: 50Sep 19, 2026: 51Sep 20, 2026: 51Sep 21, 2026: 51Sep 22, 2026: 53Sep 23, 2026: 49Sep 24, 2026: 46Sep 25, 2026: 45Sep 26, 2026: 45Sep 27, 2026: 45Sep 28, 2026: 45Sep 29, 2026: 38Sep 30, 2026: 38Oct 1, 2026: 37Oct 2, 2026: 38Oct 3, 2026: 37Oct 4, 2026: 37Oct 5, 2026: 37Oct 6, 2026: 37Oct 7, 2026: 38Oct 8, 2026: 37Oct 9, 2026: 37Oct 10, 2026: 37Oct 11, 2026: 37Oct 12, 2026: 35Oct 13, 2026: 35Oct 14, 2026: 35Oct 15, 2026: 37Oct 16, 2026: 36Oct 17, 2026: 37Oct 18, 2026: 37Oct 19, 2026: 38Oct 20, 2026: 38Oct 21, 2026: 38Oct 22, 2026: 39Oct 23, 2026: 38Oct 24, 2026: 38Oct 25, 2026: 38Oct 26, 2026: 36Oct 27, 2026: 40Oct 28, 2026: 41Oct 29, 2026: 42Oct 30, 2026: 42Oct 31, 2026: 43Nov 1, 2026: 43Nov 2, 2026: 42Nov 3, 2026: 41Nov 4, 2026: 40Nov 5, 2026: 36Nov 6, 2026: 37Nov 7, 2026: 37Nov 8, 2026: 37Nov 10, 2026: 39Nov 11, 2026: 42Nov 12, 2026: 46Nov 13, 2026: 47Nov 14, 2026: 47Nov 15, 2026: 47Nov 16, 2026: 45Nov 17, 2026: 45Nov 18, 2026: 45Nov 19, 2026: 45
Show the daily numbers
DateComposite
Nov 19, 202645
Nov 18, 202645
Nov 17, 202645
Nov 16, 202645
Nov 15, 202647
Nov 14, 202647
Nov 13, 202647
Nov 12, 202646
Nov 11, 202642
Nov 10, 202639
Nov 8, 202637
Nov 7, 202637
Nov 6, 202637
Nov 5, 202636
Nov 4, 202640
Nov 3, 202641
Nov 2, 202642
Nov 1, 202643
Oct 31, 202643
Oct 30, 202642
Oct 29, 202642
Oct 28, 202641
Oct 27, 202640
Oct 26, 202636
Oct 25, 202638
Oct 24, 202638
Oct 23, 202638
Oct 22, 202639
Oct 21, 202638
Oct 20, 202638
Oct 19, 202638
Oct 18, 202637
Oct 17, 202637
Oct 16, 202636
Oct 15, 202637
Oct 14, 202635
Oct 13, 202635
Oct 12, 202635
Oct 11, 202637
Oct 10, 202637
Oct 9, 202637
Oct 8, 202637
Oct 7, 202638
Oct 6, 202637
Oct 5, 202637
Oct 4, 202637
Oct 3, 202637
Oct 2, 202638
Oct 1, 202637
Sep 30, 202638
Sep 29, 202638
Sep 28, 202645
Sep 27, 202645
Sep 26, 202645
Sep 25, 202645
Sep 24, 202646
Sep 23, 202649
Sep 22, 202653
Sep 21, 202651
Sep 20, 202651
Sep 19, 202651
Sep 18, 202650
Sep 17, 202651
Sep 16, 202648
Sep 15, 202649
Sep 14, 202651
Sep 13, 202651
Sep 12, 202651
Sep 11, 202651
Sep 10, 202650
Sep 9, 202652
Sep 8, 202653
Sep 7, 202651
Sep 6, 202651
Sep 5, 202651
Sep 4, 202651
Sep 3, 202652
Sep 2, 202652
Sep 1, 202653
Aug 31, 202652
Aug 30, 202654
Aug 29, 202654
Aug 28, 202653
Aug 27, 202654
Aug 26, 202654
Aug 25, 202655
Aug 24, 202653
Aug 23, 202654
Aug 22, 202654

Key facts

Market cap
$1.4B
Sector
Healthcare
Industry
Biotechnology
Beta
1.13
Risk grade (1–10)
3
Next earnings
Nov 4, 2026

Questions

What is QURE's stock rating today?

QURE scores 45/100 (Weak) as of Nov 19, 2026: technical 29, fundamental 49, and news sentiment 54, which is shown but not counted. Scores are recomputed every night.

What does uniQure do?

uniQure (QURE) is a Netherlands-based gene therapy company that develops one-time treatments delivered with adeno-associated virus vectors. Its main program is AMT-130, an investigational therapy for Huntington’s disease that is infused directly into the brain and is designed to reduce production of the harmful huntingtin protein.

Is QURE stock a buy?

The score is not a buy or sell recommendation. A 45 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the QURE score calculated?

99 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

QURE stock score

HTML

<a href="https://stocksscores.com/stocks/qure/"><img src="https://stocksscores.com/stocks/qure/badge.svg" alt="QURE stock score" height="20"></a>

Markdown

[![QURE stock score](https://stocksscores.com/stocks/qure/badge.svg)](https://stocksscores.com/stocks/qure/)